

Product : Budesonide Inhalation Suspension 0.25mg/2.0ml

Date of Issue: 09.05.2017 Revision No.: 01

NDC No. : NDC 69097-318-87

1 IDENTIFICATION OF SUBSTANCE

Product Identifier: Budesonide Inhalation Suspension 0.25mg/2ml

Synonym(s) : Not Applicable

Company Name

Cipla Limited

Company Address:

Head Office

Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai, Maharashtra, India (Pin Code – 400 013)

Cipla Ltd., L-139 to L-146, Verna Industrial Estate,

Manufacturing

division

Verna, Salcette Goa - 403 722 India

Telephone : +91 832 2889114/2889112 E-mail

: sanjay.ghare@cipla.com

Fax : +91 832 /2782840

Emergency Contact

: +91 832 2889000

Web Site

: www.cipla.com

Recommended use

It is an anti-inflammatory drug (corticosteroid hormone). It works by decreasing the body's natural defense response (immune response). It may cause a serious type of allergic reaction called anaphylaxis. Anaphylaxis requires immediate medical attention. The most serious

signs of this reaction are very fast or irregular breathing, gasping for

Recommended restrictions

: breath, wheezing, or fainting. Other signs may include changes in color of the skin of the face, very fast but irregular heartbeat or pulse,

hive-like swellings on the skin, and puffiness or swellings of the

eyelids or around the eyes

2 HAZARD IDENTIFICATION

Classification as per EC -

Physical

: Data not available.

Health

Data not available.

Environmental

: Data not available

Label in accordance

with EC

This product is a non-hazardous solution of single components : and need not be labelled according to EC-Directive 1999/45/EC.

as amended.

Single Word

: Budesonide Inhalation Suspension

Hazard Statements

: Contains a pharmaceutical active ingredient

Precautionary

Statements

: Wear suitable protective clothing and gloves.

Page 1 of 8

Description of any

hazards not

: Data not available.

otherwise classified



Product : Budesonide Inhalation Suspension 0.25mg/2.0ml

Date of Issue : 09.05.2017 Revision No. : 01

NDC No. : NDC 69097-318-87

% of the mixture consisting of ingredient(S) with unknown acute

: Data not available

toxicity

3 COMPOSITION / INFORMATION ON INGREDIENTS

Chemical Name 22S and 22R epimers of 16a,17a-butylidenedioxy-11b,21-

dihydroxypregna-1,4-diene-3,20-dione

Common Name /

Synonyms

Budesonide

Molecular Formula : C₂₅H₃₄O₆

Molecular Weight : 430.53 g/mol

CAS No. : 51333-22-3

UN. No. : Information not available.

EC No. : Information not available.

Mixture (Ingredient Name,

Concentration)

Polysobrate 80, Sodium Chloride, Edetate Disodium, Citric

acid monohydrate, Sodium Citrate Dihydrate and Water for Injection

Chemicals where a trade

secret is claimed

Information not available.

4 FIRST AID MEASURES

Remove from exposure. Remove contaminated clothing. For treatment advice, seek guidance from an occupational health

physician or other licensed health- care provider familiar with

workplace chemical exposures

Inhalation : Remove from exposure and move to fresh air immediately.

May cause irritation. Flush with copious amounts of water.

Skin Contact : Seek medical advice. Flush skin with plenty of water for at least

15 minutes while removing contaminated clothing and shoes.

Eye ContactImmediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids.

09.05.2017

Page 2 of 8



Product : Budesonide Inhalation Suspension 0.25mg/2.0ml

Date of Issue: 09.05.2017 Revision No.: 01

NDC No. : NDC 69097-318-87

Ingestion If conscious, give water to drink and induce vomiting. Wash out

the mouth with water. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment Information not available

Medical conditions Information not available

caused or aggravated by

· Information not available exposure Antidote

5 FIRE FIGHTING MEASURES

The product is assumed to be combustible. Emits toxic fumes Fire and Exposure hazard

under fire condition.

Extinguishing media/

equipment

: Use water spray, carbon dioxide or dry chemical.

Special firefighting procedures and Protective

Measures

: Wear self-contained breathing apparatus (SCBA) and full turnout gear. As with all fires, evacuate person to safe area

equipment are recommended for fire-fighters.

Hazardous Combustion

Personal Precautions

Products

: Information not available

6 ACCIDENTAL RELEASE MEASURES

Avoid unwanted exposure, wear self-contained breathing

apparatus or approved respirator whichever is suitable.

chemical suit, chemically compatible hand gloves, boots and

safety goggles.

Vacuum up the material, place in a bag / container and hold for **Environmental Precaution**

waste disposal.

Place spillage in appropriate container / bag for waste

disposal. Wash contaminated clothing before reuse. Ventilate

area and wash spill site. Dispose off waste in accordance with

applicable federal state and local laws.

Decontamination

Clean-up Procedure

Procedure

: Information not available.

Methods and materials

used for containment

: Contain spill and collect, as appropriate.

Emergency Procedures

: Information not available.

Page 3 of 8



Product

: Budesonide Inhalation Suspension 0.25mg/2.0ml

Date of Issue: 09.05.2017

NDC No. : NDC 69097-318-87

Revision No.: 01

7 HANDLING AND STORAGE

Precautions for Safe

Handling

Handle material with care. This material should be handled as per instructions to ensure product integrity. Avoid contact with skin, eyes and clothing. Handle product with wearing proper personnel protective equipments mentioned in section. Wear fresh clothing daily. Wash contaminated clothing before reuse. Wash thoroughly after handling. Do not permit eating, drinking or smoking near the material.

Safe Storage

Closed container at the demarcated place. This material should be handled and stored as per instructions to ensure

product integrity.

Any Specific storage

requirements

Store in accordance with information listed on the product

insert.

8 EXPOSURE CONTROLS / PERSONAL PROTECTION

Hazard category and

Exposure limits

: Information not available.

Appropriate Engineering

Controls

Use process enclosures, local exhaust ventilation, or other

: engineering controls to control airborne levels below

recommended exposure limits.

Respiratory protection

equipment

Wear a NISOH/MSHA or European Standard EN 149

approved full face piece.

Respiratory protection

Wear a NISOH/MSHA or European Standard EN 149

approved full face piece.

Hand protection

: Wear chemical compatible hand gloves.

Eye protection

Wear safety glasses and chemical goggles if splashing is

possible.

Skin protection

: Wear appropriate laboratory apparel. Protect exposed skin.

Exposure control Ventilation

Adequate ventilation is required .Provide local exhaust and

mechanical ventilation.

Hygiene Measure

: Information not available

9 PHYSICAL AND CHEMICAL PROPERTIES

Appearance and odour

: A white to off white homogeneous redispersible suspension.

Vapour pressure

: Information not available

Vapour density

: Information not available

09.05.2017

Page 4 of 8



Product : Budesonide Inhalation Suspension 0.25mg/2.0ml

Date of Issue: 09.05.2017 Revision No.: 01

NDC No. : NDC 69097-318-87

Flash point : Information not available

Viscosity : Information not available

Boiling point : Information not available

Melting range : Information not available

Specific gravity: Information not available

Auto-ignition : Information not available

Relative density : Information not available

Flammability : Information not available

Solubility : Information not available

Explosive Limits : Information not available

Odour threshold : Information not available

pH : Information not available

Freezing Point : Information not available

Evaporation Rate : Information not available

Partition Coefficient : Information not available

Decomposition Temperature: Information not available

10STABILITY AND REACTIVITY

Chemical Stability : Information not available.

Reactivity: Information not available.

Incompatibilities / Conditions

to avoid

: Information not available.

Hazardous decomposition

products

: Information not available.

Hazardous reactions : Information not available.

Hazardous polymerization: Information not available.

11TOXICOLOGICAL INFORMATION

Symptoms on Exposure : Information not available.

Route of Exposure : Absorbed through skin, Eye contact, Inhalation, Ingestion.

Oral Toxicity : Information not available

Jay 05. 2017

Page 5 of 8



Product : Budesonide Inhalation Suspension 0.25mg/2.0ml

Date of Issue: 09.05.2017 Revision No.: 01

: NDC 69097-318-87 NDC No.

Sensitization : Information not available

Inhalation Toxicity : Information not available

Genetic Toxicity : Information not available

Skin Effects : Information not available

Carcinogenicity Information not available

Eye Effects Information not available

Reproductive effects Information not available

Target Organ Effects Information not available

Toxicity data -

SCU-RAT LD 50 : Information not available

SCU-RAT LD 50 Information not available

LD 50 (Oral, mouse) : >3200mg/kg (Budesonide)

LD 50 (Oral, mouse) : 4750mg/kg (Budesonide)

LD 50 (intraperitoneal,

: 179mg/kg (Budesonide) mouse)

12ENVIRONMENTAL / ECOLOGICAL INFORMATION

Summary : Releases to the environment should be avoided.

Ecotoxicity Information not available.

Degradability : Information not available

13 DISPOSAL CONSIDERATION

Description of appropriate disposal container to Use

: Information not available

Disposal method Recommendations

Disposal

Dispose material as per local, state and federal regulatory

procedures and laws.

Physical and Chemical properties that can affect

Dispose material as per local, state and federal regulatory

procedures and laws.

Any Special Precautions to be taken

: Information not available

Page 6 of 8



Product: Budesonide Inhalation Suspension 0.25mg/2.0ml

Date of Issue: 09.05.2017 Revision No.: 01

NDC No. : NDC 69097-318-87

Regulatory Requirements : Information not available.

14 TRANSPORT INFORMATION (Un Classification and Labelling)

UN number : Information not available.

UN proper shipping name : Information not available.

ADR Packing Group : Information not available.

ADR Class : Information not available.

Additional Pictogram : Information not available.

ADR : Information not available.

IATA : Information not available.

GHS: Information not available.

Environmental Hazards: Releases to the environment should be avoided.

Any Special Precaution (If : This is a Pharmaceutical Product there are no restrictions

any) for transportation.

15 REGULATORY INFORMATION

Labelling according to EEC

directives

: Information not available.

National legislation/regulations

: Information not available.

Any other regulatory

Information

Irritating to eyes, respiratory system and skin. Possible risks

of irreversible effects. Possible risk of harm to the unborn

child.

16 OTHER INFORMATION

SDS Prepared On : 09.05.2017

Last Revision done date : Not Applicable

Changes done to previous

version

: Not Applicable

Therapeutic Category of

material

: Anti-Asthma drug

Reference : As per API and excipient Vendor Material MSDS

Jours 2017

Page 7 of 8 (103



Revision No.: 01

SAFETY DATA SHEET

Product : Budesonide Inhalation Suspension 0.25mg/2.0ml

Date of Issue: 09.05.2017

NDC No. : NDC 69097-318-87

The information contained herein is based on the present state of our knowledge and does not therefore guarantee certain properties. The information given was obtained from sources which we believe are reliable. The information and recommendations given are to the best of our knowledge and as per data given by Quality assurance, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. Recipients of material must take responsibility for observing existing laws, regulations and suitability of material for handing transport and any particular purpose. We do not assume responsibility and expressly disclaim liability for loss, damage and expenses arising out of or in any way connected with the handling storage, use and disposal of the product information mentioned in this document relates only to the specific material designated and may not be valid for such material used in combination with other material or in any process.

Prepared By Safety

Date: 09.05 2017

Approved By
Head Unit Quality

Date: 09.05-2017

Noted By Unit Head

Date: 09.05 2017